A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Pacira Pharmaceuticals, Inc
- Enrollment
- 140
- Locations
- 17
- Primary Endpoint
- Total Postsurgical Opioid Consumption Through 48 Hours
Study Overview
Brief Summary
This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately 140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine HCl (10-15 mg).
Detailed Description
On Day 0, eligible subjects will be randomized 1:1 to two treatment groups. Subjects in Group 1 will receive local infiltration analgesia (LIA) with EXPAREL 266 mg in 20 mL admixed with bupivacaine hydrochloride (HCl) 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL). Subjects in Group 2 will receive LIA with bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL). Investigators will use their usual surgical technique to perform the TKA.
Study drug will be administered using six 20 cc syringes with 22-gauge needles prior to wound closure. Each stick should deliver approximately 1-1.5 cc to the intended area. The tissue should visibly expand with minimal leakage. Study drug should be injected in the prescribed locations based on the areas of highest nerve density.
Infiltration Technique
Prior to cementation
Syringe #1: Posterior capsule (8-10 sticks medial and 8-10 sticks lateral).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, at least 18 years of age at screening.
- •Scheduled to undergo primary, unilateral, tricompartmental TKA under spinal anesthesia.
- •Primary indication for TKA is degenerative osteoarthritis of the knee.
- •American Society of Anesthesiologists (ASA) physical status 1, 2, or
- •Female subjects must be surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner who is surgically sterile; or practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening and commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study.
- •Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.
Exclusion Criteria
- •Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
- •History of previous prior contralateral TKA or open knee surgery on the knee being considered for TKA. Prior arthroscopy is permitted.
- •Planned concurrent surgical procedure (e.g., bilateral TKA).
- •Undergoing unicompartmental TKA or revision TKA.
- •Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the knee surgery and which may confound the postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).
- •Comorbidity impacting current physical function of Investigator opinion that it may impact postsurgical rehabilitation.
- •Allergy, hypersensitivity, or contraindication to any of the study medications (i.e., bupivacaine, pregabalin, acetaminophen/paracetamol, celecoxib, oxycodone, morphine, hydromorphone, or tranexamic acid).
- •Use of any of the following medications within the times specified before surgery: long-acting opioid medication or NSAIDs (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid medication within 24 hours.
- •Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to study drug administration.
- •Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
- •Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration.
- •History of coronary or vascular stent placed within the past 3 months (may be extended to 1 year if medically indicated per physician discretion).
- •Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
- •Rheumatoid or inflammatory arthritis or disease.
- •Severely impaired renal or hepatic function (e.g., serum creatinine level >2 mg/dL [176.8 µmol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum aspartate aminotransferase [AST] level >3 times the upper limit of normal [ULN], or serum alanine aminotransferase [ALT] level >3 times the ULN.)
- •Any neurologic or psychiatric disorder that might impact postsurgical pain or interfere with study assessments.
- •Malignancy in the last 2 years, per physician discretion.
- •History of misuse, abuse, or dependence on opioid analgesics, other prescription drugs, illicit drugs, or alcohol.
- •Failure to pass the alcohol breath test or urine drug screen.
- •Body weight <50 kg (110 pounds) or a body mass index >40 kg/m
- •Previous participation in an EXPAREL study.
- •Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Arms & Interventions
EXPAREL
Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
Intervention: EXPAREL (Drug)
Bupivacaine
Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
Intervention: Bupivacaine (Drug)
Outcomes
Primary Outcomes
Total Postsurgical Opioid Consumption Through 48 Hours
Time Frame: 0-48 hours
Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours
Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours
Time Frame: From 12-48 hours
AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
Secondary Outcomes
- Percentage of Opioid-free Subjects at 48 Hours(48 hours)
- Time to First Opioid Rescue in the First 48 Hours(48 hours)
- Overall Benefit of Analgesia Score at 48 Hours(48 hours)